Stonepine Capital Management’s Edesa Biotech EDSA Stock Holding History

Stonepine Capital Management’s Portfolio EDSA Stock Details EDSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$2.99M	Buy	710,266 +253,827	+56%	+$1.33M	1.88%	18
2026 Q2	$3.19M	Buy	456,439 +426,439	+1,421%	+$3.85M	1.8%	20
2026 Q1	$157K	Sell	30,000 -657,500	-96%	-$1.97M	0.06%	74
2025 Q4	$976K	Hold	687,500	–	–	0.71%	39
2025 Q3	$1.7M	Buy	+687,500	New	+$1.59M	1.38%	18
2025 Q2	–	Sell	-687,500	Closed	-$1.68M	–	67
2025 Q1	$1.68M	Buy	+687,500	New	+$1.48M	1.63%	20

Other funds holding EDSA

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Jane Street New York $1.19T AUM 51.51% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $463B AUM

BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

Scotia Capital Toronto, Ontario, Canada $28.7B AUM 25.13% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return

Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $294B AUM 47.59% 1-Year Est. Return

Stonepine Capital Management's EDSA Position: Q3 2026 in Review

Stonepine Capital Management increased its Edesa Biotech (EDSA) stake by 56% in Q3 2026, buying an estimated $1.33M and bringing the position to 710,266 shares worth $2.99M. The position accounts for 1.88% of the portfolio, ranked #18.

Stonepine Capital Management first reported a position in EDSA in Q1 2025 and has held it in 6 quarters since. The position peaked at $3.19M in Q2 2026. 18 funds tracked by Wall St. Rank hold EDSA as of Q3 2026.

Stonepine Capital Management held 710,266 shares of Edesa Biotech worth $2.99M as of Q3 2026.
Stonepine Capital Management bought 253,827 Edesa Biotech shares in Q3 2026, an estimated $1.33M.
Edesa Biotech made up 1.88% of Stonepine Capital Management's portfolio in Q3 2026, its #18 holding.
Stonepine Capital Management first reported a position in Edesa Biotech in Q1 2025 and has held it in 6 quarters since.
Stonepine Capital Management's Edesa Biotech position peaked at $3.19M in Q2 2026.
18 funds tracked by Wall St. Rank held Edesa Biotech as of Q3 2026.

Based on Stonepine Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.